When did Gilead Sciences report Q3 2024 earnings?

Gilead Sciences (GILD) reported Q3 2024 earnings on November 6, 2024 after market close.

What were Gilead Sciences's Q3 2024 revenue and EPS?

Gilead Sciences reported revenue of $7.5B and diluted EPS of $2.02 for Q3 2024.

Did Gilead Sciences beat estimates in Q3 2024?

Revenue beat the consensus estimate of $7.0B by $529.4M. EPS beat the consensus estimate of $1.53 by $0.49.

Where can I find Gilead Sciences's Q3 2024 SEC filings?

You can read the 10-Q periodic report (0000882095-24-000028) directly on SEC EDGAR. The filing index links above go to sec.gov.

Gilead Sciences GILD Q3 2024 earnings

Reported November 6, 2024 · After market close

Revenue$7.5BBeat by $529.4M Diluted EPS$2.02Beat by $0.49

Revenue estimate$7.0B

EPS estimate$1.53

Next report

Aug 6, 2026 (in a month)

Revenue estimate$7.4B

EPS estimate-$7.20

Financials

Q3 2024

Income statement

See full

Revenue$7.5B+7.0%

Gross profit$6.0B+8.8%

Operating income$888.0M-66.1%

Net income$1.3B-42.5%

EPS (diluted)$1.00-42.2%

Balance sheet

See full

Cash & equivalents$5.0B-11.7%

Total debt$23.2B-6.9%

Total equity$18.5B-17.2%

Total assets$54.5B-12.6%

Cash flow

See full

Operating cash flow$4.3B+146%

CapEx$141.0M+15.6%

Free cash flow$4.2B+155%

Valuation & ratios

Q3 2024

Valuation

See full

Market cap$104.38B+11.8%

Enterprise value$122.59B+8.8%

P/E828.4×+813×

P/S3.7×+0.3×

Profitability

See full

Gross margin76.1%-2.7pp

Operating margin2.9%-27.3pp

Net margin0.4%-21.0pp

FCF margin33.3%+4.7pp

Returns & leverage

See full

Return on equity0.6%-26.5pp

Debt / equity1.3×+0.1×

Current ratio1.3×-0.1×

Segments

By product

See full

Biktarvy$3.5B+12.5%

Veklury$692.0M+8.8%

Descovy$586.0M+14.7%

Genvoya$449.0M-10.7%

Sofosbuvir/Velpatasvir$385.0M—

By geography

See full

Europe$1.2B+12.2%

Rest of World$929.0M—

Versus estimates

Revenue

Q1 2026$7.0BBeat by $46.6M Q4 2025$7.9BBeat by $234.6M Q3 2025$7.8BBeat by $323.6M Q2 2025$7.1BBeat by $99.5M Q1 2025$6.7BMiss by $143.9M Q4 2024$7.6BBeat by $416.5M

Diluted EPS

Q1 2026$2.03Beat by $0.12 Q4 2025$1.86Beat by $0.05 Q3 2025$2.47Beat by $0.34 Q2 2025$2.01Beat by $0.05 Q1 2025$1.81Beat by $0.03 Q4 2024$1.90Beat by $0.16

Ask the moment Gilead Sciences reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Gilead Sciences report Q3 2024 earnings?: Gilead Sciences (GILD) reported Q3 2024 earnings on November 6, 2024 after market close.
What were Gilead Sciences's Q3 2024 revenue and EPS?: Gilead Sciences reported revenue of $7.5B and diluted EPS of $2.02 for Q3 2024.
Did Gilead Sciences beat estimates in Q3 2024?: Revenue beat the consensus estimate of $7.0B by $529.4M. EPS beat the consensus estimate of $1.53 by $0.49.
Where can I find Gilead Sciences's Q3 2024 SEC filings?: You can read the 10-Q periodic report (0000882095-24-000028) directly on SEC EDGAR. The filing index links above go to sec.gov.